Management of Acute Musculoskeletal Spasm

First-Line Treatment Approach

• The American College of Physicians recommends cyclobenzaprine 5 mg three times daily or baclofen 10-30 mg/day as first-line pharmacological options for acute musculoskeletal spasm, in combination with rest and physical therapy 1, 2
• Baclofen 10-30 mg/day is an equally effective alternative, with gradual dose titration essential to avoid adverse effects 2, 3

Critical Treatment Duration

• Skeletal muscle relaxants demonstrate moderate superiority to placebo for short-term pain relief (2-4 days) in acute low back pain, with a relative risk of 0.80 for not achieving pain relief 1

Essential Non-Pharmacological Components

• The American College of Physicians emphasizes the importance of non-pharmacological interventions, including physical therapy, rest, and range-of-motion exercises, to be integrated with medication 2
• Heat, cold, and electrical stimulation may help reduce muscle spasms as adjunctive measures 3

Critical Safety Warnings

• The American Geriatrics Society strongly recommends avoiding muscle relaxants in elderly patients due to increased risk of falls, sedation, and anticholinergic effects 2
• If muscle relaxants are necessary in elderly patients, lower doses should be used due to increased risk of side effects 3

Common Adverse Effects

• All muscle relaxants cause central nervous system effects, including somnolence, fatigue, and lightheadedness, with a relative risk of 2.04 for CNS adverse events compared to placebo 1, 2

Discontinuation Protocol

• The American College of Physicians mandates a slow tapering period to prevent withdrawal symptoms when discontinuing muscle relaxants after prolonged use, particularly with baclofen 2

What NOT to Do

• The British Journal of Sports Medicine highlights the importance of avoiding opioids for musculoskeletal pain management, due to the risk of overuse and adverse effects 4, 5
• Antidepressants or anticonvulsants should not be relied upon for simple musculoskeletal spasm, and are reserved for chronic non-inflammatory pain or neuropathic pain conditions 4, 6